Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype

Respirology

Volumn 17, Issue 1, 2012, Pages 127-133

  Tseden Ish, Manaljav ^a   Choi, Yoo Duk ^a   Cho, Hyun Ju ^a   Ban, Hee Jung ^a   Oh, In Jae ^a   Kim, Kyu Sik ^a   Song, Sang Yun ^a   Na, Kook Joo ^a   Ahn, Sung Ja ^a   Choi, Song ^a   Kim, Young Chul ^a  

^a Chonnam National University   (South Korea)

Author keywords

biomarker; class III beta tubulin; excision repair cross complementation group 1; non small cell lung cancer; survival

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GENOMIC DNA;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA ISOLATION; FEMALE; GENE LOCUS; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84255176610     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02060.x     Document Type: Article

References (30)

1. Park YS, Kim SH, Park SK, et al,. Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea. Lung Cancer 2010; 68: 299-304.
2. Pignon JP, Tribodet H, Scagliotti GV, et al,. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008; 26: 3552-9.
3. Ikeda N, Nagase S, Ohira T,. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers. Ann. Thorac. Cardiovasc. Surg. 2009; 15: 144-9.
4. Reed E,. ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res. 2005; 11: 6100-2. (Pubitemid 41262934)
5. Zamble DB, Mu D, Reardon JT, et al,. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996; 35: 10004-13. (Pubitemid 26269915)
6. Rosell R,. The predictive and prognostic roles of ERCC1 expression and Akin DNA repair genes in non-small-cell lung cancer: M06-01. J. Thorac. Oncol. 2007; 2: S166-7.
7. Fujii T, Toyooka S, Ichimura K, et al,. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008; 59: 377-84. (Pubitemid 351335101)
8. Liang J, Lv H, Yao R, et al,. ERCC1 Asn118Asn polymorphism as predictor for cancer response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Chin Ger J Clin Oncol 2008; 7: 455-9.
9. Takenaka T, Yano T, Kiyohara C, et al,. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010; 67: 101-7.
10. Cicchillitti L, Penci R, Di Michele M, et al,. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol. Cancer Ther. 2008; 7: 2070-9.
11. Forde JC, Perry AS, Brennan K, et al,. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. Urol. Oncol. 2010. Epub ahead of print; doi: 10.1016/j.urolonc.2010.08.015.
12. Koh Y, Kim TM, Jeon YK, et al,. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann. Oncol. 2009; 20: 1414-19.
13. Koh Y, Jang B, Han SW, et al,. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J. Thorac. Oncol. 2010; 5: 320-5.
14. Goldstraw P, Crowley J, Chansky K, et al,. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J. Thorac. Oncol. 2007; 2: 706-14. (Pubitemid 47357522)
15. Schemper M, Smith TL,. A note on quantifying follow-up in studies of failure time. Control. Clin. Trials 1996; 17: 343-6. (Pubitemid 26342716)
16. Olaussen KA, Dunant A, Fouret P, et al,. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006; 355: 983-91. (Pubitemid 44343542)
17. Simon GR, Sharma S, Cantor A, et al,. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127: 978-83. (Pubitemid 40775532)
18. Holm B, Mellemgaard A, Skov T, et al,. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J. Clin. Oncol. 2009; 27: 4254-9.
19. Bepler G, Olaussen KA, Vataire AL, et al,. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am. J. Pathol. 2011; 178: 69-78.
20. Zheng Z, Chen T, Li X, et al,. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 2007; 356: 800-8. (Pubitemid 46294612)
21. Ceppi P, Volante M, Novello S, et al,. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 2006; 17: 1818-25. (Pubitemid 44884058)
22. Lord RV, Brabender J, Gandara D, et al,. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002; 8: 2286-91. (Pubitemid 34753602)
23. Reiman T, Lai R, Veillard AS, et al,. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann. Oncol. 2011. Epub ahead of print; doi: 10.1093/annonc/mdr033.
24. Izutsu N, Maesawa C, Shibazaki M, et al,. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int. J. Oncol. 2008; 32: 1227-35.
25. Park SY, Hong YC, Kim JH, et al,. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med. Oncol. 2006; 23: 489-98.
26. Ryu JS, Hong YC, Han HS, et al,. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311-16.
27. Kalikaki A, Kanaki M, Vassalou H, et al,. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer 2009; 10: 118-23.
28. Zhou C, Ren S, Zhou S, et al,. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn. J. Clin. Oncol. 2010; 40: 954-60.
29. Zhou W, Gurubhagavatula S, Liu G, et al,. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 2004; 10: 4939-43. (Pubitemid 39099767)
30. Chang PM, Tzeng CH, Chen PM, et al,. ERCC1 codon 118 CâT polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci. 2009; 100: 278-83.